TERPSIS STUDY
DEAD

Add to watchlist:

No watchlists yet
View on USPTO

TERPSIS STUDY Trademark

Serial Number: 90833550

TERPSIS STUDY is a trademark filed by Neurocrine Biosciences, Inc. on July 16, 2021. The trademark is classified under Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently no longer active.

Owner Contact Info

Neurocrine Biosciences, Inc. (237 trademarks)

6027 Edgewood Bend Court
San Diego, CA 92130

Entity Type: 03

Trademark Details

Filing Date

July 16, 2021

Registration Date

Not Registered

Published for Opposition

May 3, 2022

Goods & Services

Providing medical information; providing medical information relating to therapies and treatments for anhedonia, major depressive disorder and mood disorders

Pharmaceutical research and development services; conducting clinical trials for others for pharmaceutical preparations; pharmaceutical research services and pharmaceutical product evaluation, namely, conducting post-authorization research for the marketing of pharmaceutical preparations and evaluating epidemiological results; pharmaceutical research and development services in the field of anhedonia, major depressive disorder and mood disorders; conducting clinical trials for others for pharmaceutical preparations for the treatment and prevention of anhedonia, major depressive disorder and mood disorders; pharmaceutical research services and pharmaceutical product evaluation, namely, conducting post-authorization research for the marketing of pharmaceutical preparations for the treatment and prevention of anhedonia, major depressive disorder and mood disorders, and evaluating epidemiological results for treatments for anhedonia, major depressive disorder and mood disorders; providing medical and scientific research information to patients and practitioners in the field of clinical trials, namely, as to the results of clinical trials; providing medical and scientific research information to patients and practitioners in the field of clinical trials, namely, as to the results of clinical trials pertaining to therapies and treatments for anhedonia, major depressive disorder and mood disorders

Filing History

ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Oct 7, 2025 MAB6
ABANDONMENT - NO USE STATEMENT FILED
Oct 7, 2025 ABN6
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Jun 13, 2024 EXRA
SOU EXTENSION 4 GRANTED
Jun 13, 2024 EX4G
SOU EXTENSION 4 FILED
Jun 13, 2024 EXT4
SOU TEAS EXTENSION RECEIVED
Jun 13, 2024 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Dec 21, 2023 EXRA
SOU EXTENSION 3 GRANTED
Dec 19, 2023 EX3G
SOU EXTENSION 3 FILED
Dec 19, 2023 EXT3
SOU TEAS EXTENSION RECEIVED
Dec 19, 2023 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Jun 20, 2023 EXRA
SOU EXTENSION 2 GRANTED
Jun 16, 2023 EX2G
SOU EXTENSION 2 FILED
Jun 16, 2023 EXT2
SOU TEAS EXTENSION RECEIVED
Jun 16, 2023 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Oct 18, 2022 EXRA
SOU EXTENSION 1 GRANTED
Oct 14, 2022 EX1G
SOU EXTENSION 1 FILED
Oct 14, 2022 EXT1
SOU TEAS EXTENSION RECEIVED
Oct 14, 2022 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Jun 28, 2022 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
May 3, 2022 NPUB
PUBLISHED FOR OPPOSITION
May 3, 2022 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Apr 13, 2022 NONP
LAW OFFICE PUBLICATION REVIEW COMPLETED
Mar 31, 2022 PREV
ASSIGNED TO LIE
Mar 30, 2022 ALIE
APPROVED FOR PUB - PRINCIPAL REGISTER
Mar 29, 2022 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Mar 28, 2022 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Mar 27, 2022 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Mar 27, 2022 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Sep 29, 2021 GNRN
NON-FINAL ACTION E-MAILED
Sep 29, 2021 GNRT
NON-FINAL ACTION WRITTEN
Sep 29, 2021 CNRT
ASSIGNED TO EXAMINER
Sep 21, 2021 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Sep 20, 2021 NWOS
NEW APPLICATION ENTERED
Jul 20, 2021 NWAP